(vianews) - the market ended the session with poxel (poxel.pa) rising 34.96% to €0.94 on tuesday while cac 40 slid 0.46% to €7,339.27.
poxel's last close was €0.70, 78.71% below its 52-week high of €3.28.
about poxel
poxel s.a., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. the company's lead product is twymeeg (imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in japan. it also develops pxl770, an adenosine monophosphate-activated protein kinase enzyme, which is in a phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (nash). poxel s.a. has a licensing agreement with enyo pharma s.a.s. for the development of farnesoid x receptor that is in phase 2a study for the treatment of hepatitis b and nash; and deuterx llc for the development of pxl065, a mitochondrial pyruvate carrier inhibitor, which is in a phase i clinical trial for the treatment of nash. the company was incorporated in 2009 and is headquartered in lyon, france.
earnings per share
as for profitability, poxel has a trailing twelve months eps of €-1.02.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -323.36%.moving average
poxel's value is above its 50-day moving average of €0.91 and way under its 200-day moving average of €1.51.stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, poxel's stock is considered to be oversold (<=20).
yearly top and bottom value
poxel's stock is valued at €0.94 at 21:40 est, way under its 52-week high of €3.28 and way above its 52-week low of €0.65.
volume
today's last reported volume for poxel is 1104540 which is 1485.19% above its average volume of 69679.
more news about poxel (poxel.pa).